Ratings Quantum-Si incorporated

Equities

QSI

US74765K1051

Delayed Nasdaq Other stock markets 02:35:27 2024-05-21 pm EDT			5-day change	1st Jan Change
1.72 ^USD	-2.82%		-6.56%	-14.93%

May. 15	Transcript : Quantum-Si incorporated - Shareholder/Analyst Call
May. 09	Transcript : Quantum-Si incorporated, Q1 2024 Earnings Call, May 09, 2024

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
QUANTUM-SI INCORPORATED	-14.93%	251M	-
MODERNA, INC.	+42.59%	54.04B	B-
LONZA GROUP AG	+43.57%	41.96B	A
IQVIA HOLDINGS INC.	-1.30%	41.92B	B
CELLTRION, INC.	-7.59%	28.35B	C
ICON PUBLIC LIMITED COMPANY	+11.72%	26.35B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.02%	19B	B
BIO-TECHNE CORPORATION	+7.69%	13B	B+
MEDPACE HOLDINGS, INC.	+28.43%	12.28B	C+
UNITED THERAPEUTICS CORPORATION	+25.69%	12.19B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes